Effectiveness of a Pragmatic, Metabolic Care Clinic for Patients With Severe Mental Illness - The Meta Care Clinic

NARecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

October 10, 2023

Primary Completion Date

November 30, 2026

Study Completion Date

December 31, 2026

Conditions
Severe Mental DisorderMetabolic ComplicationSide-Effect;MedicationSchizophrenia Spectrum and Other Psychotic DisordersBipolar Disorder
Interventions
OTHER

Treatment in the Meta Care Clinic

"* Consultations by medical doctors with specific metabolic training from the metabolic clinic located at Centre for Addiction and Mental Health in Toronto, Canada, and an exercise physiologist.~* Evaluation of their psychopharmacotherapy with consultation and detailed recommendations to the patients' treating psychiatrist and/or general practitioner regarding dosage reductions or switching of psychotropics if this is clinically feasible to reduce the metabolic burden.~* Lifestyle interventions~* Pharmacotherapy with evidence to support use to mitigate antipsychotic-induced weight gain~* Treatment of other cardiovascular risk factors such as dyslipidaemia, hypertension, smoking and diabetes in close collaboration with recognized specialists in endocrinology.~* Assessment of plans at conferences with participation of the sponsor, the primary investigator as well as recognized specialists in endocrinology and psychiatry.~* Qualitative interviews will be conducted post-intervention."

OTHER

Standard care with general practitioner and/or outpatient clinics

"Following measurements after 12 months, patients will receive individualized lifestyle recommendations from an exercise physiologist and a MD will offer to send recommendations regarding the following potential post-trial interventions to the patient's general practitioner and/or outpatient clinic prepared in close collaboration with recognized specialists in psychiatry and endocrinology:~* Suggestions regarding relevant psychotropic medication adjustments or switches if this is found relevant and clinically feasible to reduce the metabolic burden.~* Suggestions regarding potential add-on of weight reducing pharmacotherapy.~* Suggestions regarding pharmacological treatment of other cardiovascular risk factors such as dyslipidaemia, hypertension, smoking and type 2 diabetes."

Trial Locations (1)

2600

RECRUITING

Centre for Neuropsychiatric Schizophrenia Research, CNSR, Mental Health Centre Glostrup, Glostrup Municipality

All Listed Sponsors
collaborator

Mental Health Centre Glostrup

UNKNOWN

collaborator

University of Toronto

OTHER

collaborator

Herlev and Gentofte Hospital

OTHER

lead

Bjorn H. Ebdrup

OTHER